GammaDelta Therapeutics Ltd. has appointed Dr. Michael Koslowski as chief medical officer. Dr. Koslowski brings over 20 years of discovery and developing immunotherapeutic drugs experience to the company. His most recent role has seen him serve as EVP of Research Development and CMO of Mission Therapeutics Ltd, where he was responsible for developing the company's pipeline of deubiquitinating enzyme inhibitors. Prior to working at Mission Therapeutics, Dr. Koslowski worked as VP of Clinical Sciences Early Development at Glenmark Pharmaceuticals (NSE: GLENMARK) where he was responsible for leading all clinical activities.